Koninklijke Philips (NYSE:PHG) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Koninklijke Philips (NYSE:PHG) have received an average rating of “Moderate Buy” from the five ratings firms that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company.

Several analysts have recently weighed in on PHG shares. BNP Paribas raised shares of Koninklijke Philips from a “neutral” rating to an “outperform” rating in a report on Tuesday, February 25th. StockNews.com upgraded Koninklijke Philips from a “hold” rating to a “buy” rating in a research report on Saturday, March 8th. UBS Group upgraded Koninklijke Philips from a “neutral” rating to a “buy” rating in a report on Thursday, February 20th. Finally, Sanford C. Bernstein upgraded shares of Koninklijke Philips from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 18th.

Institutional Investors Weigh In On Koninklijke Philips

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Bessemer Group Inc. increased its position in Koninklijke Philips by 2,935.4% in the first quarter. Bessemer Group Inc. now owns 1,973 shares of the technology company’s stock worth $51,000 after purchasing an additional 1,908 shares during the period. Aurora Private Wealth Inc. acquired a new stake in shares of Koninklijke Philips during the 1st quarter worth approximately $1,695,000. Wealthquest Corp bought a new stake in shares of Koninklijke Philips during the first quarter worth approximately $116,000. Global Assets Advisory LLC acquired a new position in Koninklijke Philips in the first quarter valued at approximately $445,000. Finally, Oppenheimer Asset Management Inc. boosted its stake in Koninklijke Philips by 1.5% in the first quarter. Oppenheimer Asset Management Inc. now owns 164,789 shares of the technology company’s stock valued at $4,186,000 after acquiring an additional 2,464 shares during the last quarter. Institutional investors own 13.67% of the company’s stock.

Koninklijke Philips Price Performance

Koninklijke Philips stock opened at $25.05 on Tuesday. The business has a 50 day simple moving average of $25.09 and a 200 day simple moving average of $26.40. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.23 and a quick ratio of 0.74. The company has a market capitalization of $23.55 billion, a PE ratio of -29.82, a price-to-earnings-growth ratio of 0.82 and a beta of 0.81. Koninklijke Philips has a one year low of $21.48 and a one year high of $32.91.

Koninklijke Philips (NYSE:PHG) last issued its quarterly earnings data on Wednesday, February 19th. The technology company reported $0.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.01). Koninklijke Philips had a negative net margin of 3.88% and a positive return on equity of 10.85%. The company had revenue of $5.38 billion for the quarter, compared to the consensus estimate of $5.10 billion. On average, sell-side analysts forecast that Koninklijke Philips will post 1.63 EPS for the current fiscal year.

Koninklijke Philips Cuts Dividend

The company also recently disclosed an annual dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 13th will be given a $0.886 dividend. The ex-dividend date is Tuesday, May 13th. This represents a yield of 2.9%. Koninklijke Philips’s payout ratio is -89.29%.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.